finanzen.net

SCICLONE PHARMACEUTICALS solides Investment

Seite 1 von 1
neuester Beitrag: 03.03.10 14:28
eröffnet am: 08.01.10 13:09 von: macos Anzahl Beiträge: 5
neuester Beitrag: 03.03.10 14:28 von: macos Leser gesamt: 2299
davon Heute: 1
bewertet mit 19 Sternen

08.01.10 13:09
19

2227 Postings, 4090 Tage macosSCICLONE PHARMACEUTICALS solides Investment

Umsatz 2009 ca 75 Mio Dollar  
MK ca 120 Mio Dollar
profitabel EPS von 0,18 - 0,22
Unternehmenspräsentation
http://files.shareholder.com/downloads/SCLN/...resentation_120109.pdf

http://www.sciclone.com/  

11.01.10 13:30
15

2227 Postings, 4090 Tage macosFinancial Update

SciClone Provides 2009 Financial Update
and Initial 2010 Sales Revenue Guidance


-- For 2009, the company anticipates revenues of approximately $72.4 million (unaudited), a 34% increase over 2008.-- Cash, cash equivalents, short and long-term investments are anticipated to be approximately $31.8 million (unaudited) at December 31, 2009, compared with $29.7 million at December 31, 2008.-- The company expects 2010 sales revenue of $82 to $85 million, a 15% increase over 2009

http://finance.yahoo.com/news/...2009-iw-1194964842.html?x=0&.v=1  

12.01.10 14:48
17

2227 Postings, 4090 Tage macosNews

SciClone and Sigma-Tau Announce Positive Preliminary Results in Clinical Study Examining ZADAXIN'S Ability to Enhance Response to H1N1 Vaccine
Study Shows Increase in Seroconversion From 56% to 88% 21 Days After Vaccination

http://finance.yahoo.com/news/...aTau-iw-1790607853.html?x=0&.v=1  

01.02.10 13:01
18

2227 Postings, 4090 Tage macosPerle mit überschaubarem Risiko

TREND INVEST REPORT - SciClone Pharmaceuticals Biotech-Perle
13:11 29.01.10

Kulmbach (aktiencheck.de AG) - Nach Einschätzung der Experten vom "TREND INVEST REPORT" ist die Aktie von SciClone Pharmaceuticals (Profil) eine unentdeckte Biotech-Perle mit überschaubarem Risiko
http://www.ariva.de/news/...Biotech-Perle-TREND-INVEST-REPORT-3228500  

03.03.10 14:28
13

2227 Postings, 4090 Tage macos4Q profit on sales

NEW YORK (AP) -- SciClone Pharmaceuticals Inc. reported a fourth-quarter profit on higher sales of the vaccine booster Zadaxin and lower costs.

The company earned $2.4 million, or 5 cents per share, compared with a loss of $3.1 million, or 7 cents per share, a year earlier. Revenue rose to $18.1 million from $15.3 million.

The results topped the average analyst estimate for a profit of 2 cents per share and revenue of $18 million, according to a survey by Thomson Reuters.

For the full year, SciClone Pharmaceuticals earned $11.9 million, or 25 cents per share, compared with a loss of $8.3 million, or 18 cents per share, in 2008. Revenue rose to $72.4 million from $54.1 million.

Looking ahead, the company expects profit between 31 cents per share and 35 cents per share on revenue between $82 million and $85 million in 2010.

In after-hours trading, shares advanced 19 cents, or 5.4 percent, to $3.69, from the regular close of $3.50.
http://finance.yahoo.com/news/...-4Q-apf-2297286264.html?x=0&.v=2  

   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Microsoft Corp.870747
Deutsche Bank AG514000
Daimler AG710000
Wirecard AG747206
Scout24 AGA12DM8
Apple Inc.865985
Amazon906866
Allianz840400
TeslaA1CX3T
BMW AG519000
E.ON SEENAG99
NEL ASAA0B733
Infineon AG623100
BASFBASF11
Siemens AG723610